This, in turn, raises the intriguing possibility that these compounds might be particularly effective as chemotherapeutic agents for the treatment of tumors that are driven by deregulated MYB, like AML or childhood T-ALL, where addiction to high levels of MYB expression or MYB rearrangements and de-novo MYB binding sites upstream of the TAL1 gene have been reported in a number of cases8–13. The gene discussed is MYB; the disease is acute lymphoblastic leukemia.